Search results
Mar 30, 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Recommendation
- Rationale
- References
The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).
The Panel’s recommendation is primarily informed by adequately powered, randomized trials of ivermectin that reported clinical outcomes. Studies that randomized participants to receive ivermectin or a matched placebo had the greatest impact on the Panel’s recommendation.6-13
Trials have failed to find a clinical benefit of using ivermectin to treat COVID-19 in outpatients. In TOGETHER, an adaptive platform trial conducted in Brazil, there was no apparent difference between the ivermectin and placebo arms for the primary outcome of risk of emergency department visits or hospitalization (14.7% vs. 16.4%).14 In addition, there was no statistically significant difference between the ivermectin and placebo arms in mortality (3.1% vs. 3.5%). In COVID-OUT, a randomized factorial trial, the use of ivermectin did not reduce the occurrence of a composite outcome of emergency department visits, hospitalization, or death when compared with a matched control (5.7% vs. 4.1%).6
Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445-455. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25130507.
Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325-332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26954318.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32251768.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32314704.
Apr 5, 2024 · Here’s What You Need to Know. The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals. The FDA has determined that currently...
Mar 30, 2022 · Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among...
Jun 21, 2021 · Meta-analysis of these 3 trials, assessing 738 participants, found that ivermectin prophylaxis among health care workers and COVID-19 contacts probably reduces the risk of COVID-19 infection by an average of 86% (79%–91%) (3 trials, 738 participants; aRR 0.14, 95% CI 0.09–0.21; 5.0% vs. 29.6% contracted COVID-19, respectively; low-certainty ...
Sep 16, 2021 · SciCheck Digest. Studies on whether ivermectin is beneficial in treating COVID-19 patients haven’t been conclusive, and health officials have warned people not to self-medicate. But...
